Your browser doesn't support javascript.
The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Lai, Chih-Cheng; Chen, Wang-Chun; Chen, Ching-Yi; Wei, Yu-Feng.
  • Lai CC; a Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Chen WC; Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan.
  • Chen CY; Department of Pharmacy, E-Da Hospital, Kaohsiung, Taiwan.
  • Wei YF; Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Expert Rev Anti Infect Ther ; 20(10): 1333-1340, 2022 10.
Article in English | MEDLINE | ID: covidwho-1915426
ABSTRACT

OBJECTIVES:

Severe-to-critical COVID-19 has been associated with exaggerated immune responses, and anti-inflammatory agents including corticosteroid and interleukin-6 antagonist have been repurposed as the treatment modality against severe SARS-CoV-2 infections. However, the clinical efficacy and safety of intravenous immunoglobulin (IVIG) in the treatment of patients with COVID-19 was controversial.

METHODS:

This meta-analysis of randomized controlled trials (RCTs) investigated the effectiveness of IVIG in patients with COVID-19. Electronic databases were searched for RCTs that compared the clinical efficacy of IVIG with standard of care or placebo in the hospitalized patients with COVID-19 were included.

RESULTS:

Six RCTs involving 472 patients were included. Patients who received IVIG had a similar mortality rate to the controls (25.3% vs 27.0%, odds ratio [OR], 0.60; 95% confidence interval [CI], 0.27-1.31). Compared with the control group, the study group demonstrated a similar incidence of receiving mechanical ventilation (OR, 0.70; 95% CI, 0.45-1.11), intensive care unit (ICU) admission (OR, 0.58; 95% CI, 0.22-1.53), length of hospital stay (mean difference [MD], -1.81 days; 95% CI, -8.42 to 4.81) and ICU stay (MD, -0.61 days; 95% CI, -2.80 to 1.58).

CONCLUSIONS:

The administration of IVIG in hospitalized patients with COVID-19 does not improve clinical outcomes.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulins, Intravenous / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Expert Rev Anti Infect Ther Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 14787210.2022.2098112

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulins, Intravenous / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: Expert Rev Anti Infect Ther Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: 14787210.2022.2098112